Pixuvri, also known by its generic name pixantrone, is a cancer medication specifically designed for the treatment of non-Hodgkin lymphoma, a type of cancer that originates in the lymphatic system. It belongs to the class of drugs known as anthracenediones, which are structurally related to anthracyclines, a group of chemotherapy drugs that interfere with the DNA replication process in cancer cells, thereby inhibiting their growth and proliferation. Pixuvri is particularly used in patients who have received other treatments that have not been successful. It is administered intravenously and works by binding to DNA and interfering with the normal DNA repair mechanism, leading to the accumulation of DNA damage in cancer cells and ultimately causing their death. This medication offers a therapeutic option for patients with relapsed or refractory non-Hodgkin lymphoma, providing a targeted approach to manage this challenging condition.